



Weill Cornell Medicine

Dual HPLC-TLC Platform for Enhanced Quality Control of Alpha-Emitting Radiotherapeutics

Lead Inventors:

James Kelly, Ph.D.

Assistant Professor of Radiopharmaceutical Sciences in Radiology,
Radiology, Weill Cornell Medical College

Business Development Contact:

Donna J. Rounds

Associate Director, Business Development and Licensing

(646) 780-8775

[dj296@cornell.edu](mailto:djr296@cornell.edu)

Dual HPLC-TLC Platform for Enhanced Quality Control of Alpha-Emitting Radiotherapeutics

Background & Unmet Need

- Radiopharmaceuticals using alpha-emitting isotopes like Ac-225 are emerging as powerful therapeutic tools for treating cancer
- Current quality control methods using radioHPLC or radioTLC alone cannot accurately assess the purity of complex alpha-emitting compounds
- Rapid, accurate purity verification is critical for patient safety and regulatory compliance in radiopharmaceutical production
- Manual handling of radioactive samples increases personnel exposure risks
- **Unmet Need:** A standardized method of accurate and rapid quality control analysis of complex radiopharmaceuticals that does not compromise analytical precision and minimizes radiation exposure

Technology Overview

- **The Technology:** An integrated HPLC-radioTLC analysis platform for precise radiopharmaceutical quality control
- The platform features a chemically resistant moving stage with protective cover, compatible with multiple radioTLC scanner models
- The system uses disposable inserts with absorption-lined wells to prevent cross-contamination
- **PoC Data:** A working prototype has been validated across multiple radionuclides (²²⁵Ac and ¹³⁴Ce) and diverse radiopharmaceutical types including small molecules, peptides, antibodies, and nanoparticles.
- The platform demonstrates rapid analysis times (~30 minutes) while maintaining robust analytical integrity

Inventors:

James Kelly
Anja Wacker

Patents:

US Application Filed

Biz Dev Contact:

Donna J. Rounds
(646) 780-8775
[dj296@cornell.edu](mailto:djr296@cornell.edu)

Cornell Reference:

D-11437



Weill Cornell Medicine

Dual HPLC-TLC Platform for Enhanced Quality Control of Alpha-Emitting Radiotherapeutics

Technology Applications

- Quality control analysis in GMP radiopharmaceutical manufacturing
- Clinical radiopharmacy operations requiring standardized QC procedures
- Analysis of novel radiotherapeutics in research settings

Technology Advantages

- Enables precise identification of radiolabeled compounds and their impurities
- Reduces operator radiation exposure through improved handling design
- Compatible with existing radioTLC equipment through versatile stage design
- Accommodates both manual and automated fraction collection methods

Supporting Data / Figures




Figure 1: Prototype of the integrated HPLC-radioTLC platform showing the 3D-printed customizable moving stage with disposable insert installed in a commercial radioTLC scanner.

Inventors:

James Kelly
Anja Wacker

Patents:

US Application Filed

Biz Dev Contact:

Donna J. Rounds
(646) 780-8775
[dj296@cornell.edu](mailto:djr296@cornell.edu)

Cornell Reference:

D-11437



Weill Cornell Medicine



Weill Cornell Medicine